Brian C. Stephenson Sells 8,500 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 8,500 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $33.19, for a total value of $282,115.00. Following the transaction, the chief financial officer now directly owns 102,464 shares in the company, valued at $3,400,780.16. The trade was a 7.66 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

BridgeBio Pharma Price Performance

NASDAQ BBIO traded up $0.85 during trading on Thursday, hitting $34.30. The company’s stock had a trading volume of 4,057,719 shares, compared to its average volume of 3,190,594. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $39.47. The company has a market cap of $6.52 billion, a PE ratio of -12.04 and a beta of 1.07. The business’s 50 day simple moving average is $32.35 and its 200-day simple moving average is $28.17.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The company had revenue of $5.88 million for the quarter, compared to the consensus estimate of $4.04 million. Analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Institutional Investors Weigh In On BridgeBio Pharma

Large investors have recently made changes to their positions in the stock. Polar Asset Management Partners Inc. acquired a new stake in BridgeBio Pharma during the 3rd quarter worth about $1,286,000. First Turn Management LLC purchased a new position in shares of BridgeBio Pharma in the third quarter worth about $10,178,000. Janus Henderson Group PLC raised its stake in shares of BridgeBio Pharma by 11.7% in the third quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company’s stock worth $122,658,000 after purchasing an additional 505,481 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of BridgeBio Pharma during the third quarter worth about $1,136,000. Finally, Principal Financial Group Inc. boosted its position in BridgeBio Pharma by 1.8% in the third quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company’s stock valued at $29,155,000 after buying an additional 19,978 shares during the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on BBIO shares. Evercore ISI upped their price target on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, December 23rd. Scotiabank upped their target price on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Friday, February 21st. Citigroup increased their target price on BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Bank of America boosted their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $95.00 price objective on shares of BridgeBio Pharma in a research report on Friday, February 21st. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, BridgeBio Pharma has a consensus rating of “Moderate Buy” and a consensus target price of $51.67.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.